JP2017522267A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017522267A5 JP2017522267A5 JP2016568387A JP2016568387A JP2017522267A5 JP 2017522267 A5 JP2017522267 A5 JP 2017522267A5 JP 2016568387 A JP2016568387 A JP 2016568387A JP 2016568387 A JP2016568387 A JP 2016568387A JP 2017522267 A5 JP2017522267 A5 JP 2017522267A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- adenoviral vector
- capsid
- polypeptide
- vector
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 27
- 206010028980 Neoplasm Diseases 0.000 claims description 18
- 201000011510 cancer Diseases 0.000 claims description 13
- 230000028993 immune response Effects 0.000 claims description 6
- 206010009944 Colon cancer Diseases 0.000 claims description 5
- 208000003445 Mouth Neoplasms Diseases 0.000 claims description 5
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 4
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 4
- 206010038389 Renal cancer Diseases 0.000 claims description 4
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 4
- 208000002458 carcinoid tumor Diseases 0.000 claims description 4
- 201000010881 cervical cancer Diseases 0.000 claims description 4
- 201000000052 gastrinoma Diseases 0.000 claims description 4
- 201000010982 kidney cancer Diseases 0.000 claims description 4
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 4
- 201000002528 pancreatic cancer Diseases 0.000 claims description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 4
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 3
- 201000002313 intestinal cancer Diseases 0.000 claims description 3
- 201000007270 liver cancer Diseases 0.000 claims description 3
- 208000014018 liver neoplasm Diseases 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 201000008968 osteosarcoma Diseases 0.000 claims description 3
- 206010038038 rectal cancer Diseases 0.000 claims description 3
- 201000001275 rectum cancer Diseases 0.000 claims description 3
- 241000701161 unidentified adenovirus Species 0.000 claims description 3
- 206010061424 Anal cancer Diseases 0.000 claims description 2
- 208000007860 Anus Neoplasms Diseases 0.000 claims description 2
- 206010004272 Benign hydatidiform mole Diseases 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010007270 Carcinoid syndrome Diseases 0.000 claims description 2
- 208000005243 Chondrosarcoma Diseases 0.000 claims description 2
- 208000006332 Choriocarcinoma Diseases 0.000 claims description 2
- 206010014733 Endometrial cancer Diseases 0.000 claims description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 2
- 208000006168 Ewing Sarcoma Diseases 0.000 claims description 2
- 201000008808 Fibrosarcoma Diseases 0.000 claims description 2
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims description 2
- 206010067807 Gingival cancer Diseases 0.000 claims description 2
- 206010018404 Glucagonoma Diseases 0.000 claims description 2
- 208000017604 Hodgkin disease Diseases 0.000 claims description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 2
- 208000006937 Hydatidiform mole Diseases 0.000 claims description 2
- 208000005016 Intestinal Neoplasms Diseases 0.000 claims description 2
- 208000007766 Kaposi sarcoma Diseases 0.000 claims description 2
- 206010062038 Lip neoplasm Diseases 0.000 claims description 2
- 208000032271 Malignant tumor of penis Diseases 0.000 claims description 2
- 208000015021 Meningeal Neoplasms Diseases 0.000 claims description 2
- 206010027406 Mesothelioma Diseases 0.000 claims description 2
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 claims description 2
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims description 2
- 206010029260 Neuroblastoma Diseases 0.000 claims description 2
- 208000005890 Neuroma Diseases 0.000 claims description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 2
- 201000010133 Oligodendroglioma Diseases 0.000 claims description 2
- 208000010191 Osteitis Deformans Diseases 0.000 claims description 2
- 208000000035 Osteochondroma Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 208000027868 Paget disease Diseases 0.000 claims description 2
- 208000000821 Parathyroid Neoplasms Diseases 0.000 claims description 2
- 208000002471 Penile Neoplasms Diseases 0.000 claims description 2
- 206010034299 Penile cancer Diseases 0.000 claims description 2
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 claims description 2
- 206010034811 Pharyngeal cancer Diseases 0.000 claims description 2
- 206010036832 Prolactinoma Diseases 0.000 claims description 2
- 201000000582 Retinoblastoma Diseases 0.000 claims description 2
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 claims description 2
- 206010061934 Salivary gland cancer Diseases 0.000 claims description 2
- 206010039491 Sarcoma Diseases 0.000 claims description 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 2
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims description 2
- 102000005157 Somatostatin Human genes 0.000 claims description 2
- 108010056088 Somatostatin Proteins 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 208000000389 T-cell leukemia Diseases 0.000 claims description 2
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 claims description 2
- 206010042971 T-cell lymphoma Diseases 0.000 claims description 2
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims description 2
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 2
- 206010057644 Testis cancer Diseases 0.000 claims description 2
- 206010043515 Throat cancer Diseases 0.000 claims description 2
- 208000000728 Thymus Neoplasms Diseases 0.000 claims description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 2
- 206010062129 Tongue neoplasm Diseases 0.000 claims description 2
- 206010044002 Tonsil cancer Diseases 0.000 claims description 2
- 208000006842 Tonsillar Neoplasms Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 2
- 208000014070 Vestibular schwannoma Diseases 0.000 claims description 2
- 206010047741 Vulval cancer Diseases 0.000 claims description 2
- 208000004354 Vulvar Neoplasms Diseases 0.000 claims description 2
- 208000008383 Wilms tumor Diseases 0.000 claims description 2
- 201000008629 Zollinger-Ellison syndrome Diseases 0.000 claims description 2
- 208000004064 acoustic neuroma Diseases 0.000 claims description 2
- 201000005188 adrenal gland cancer Diseases 0.000 claims description 2
- 208000024447 adrenal gland neoplasm Diseases 0.000 claims description 2
- 230000001093 anti-cancer Effects 0.000 claims description 2
- 230000002924 anti-infective effect Effects 0.000 claims description 2
- 230000000259 anti-tumor effect Effects 0.000 claims description 2
- 201000011165 anus cancer Diseases 0.000 claims description 2
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 201000010918 connective tissue cancer Diseases 0.000 claims description 2
- 230000002124 endocrine Effects 0.000 claims description 2
- 201000004101 esophageal cancer Diseases 0.000 claims description 2
- 208000024519 eye neoplasm Diseases 0.000 claims description 2
- 201000010175 gallbladder cancer Diseases 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 230000002496 gastric effect Effects 0.000 claims description 2
- 208000015419 gastrin-producing neuroendocrine tumor Diseases 0.000 claims description 2
- 201000007116 gestational trophoblastic neoplasm Diseases 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- 201000010235 heart cancer Diseases 0.000 claims description 2
- 208000024348 heart neoplasm Diseases 0.000 claims description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 2
- 206010022498 insulinoma Diseases 0.000 claims description 2
- 201000006721 lip cancer Diseases 0.000 claims description 2
- 208000022006 malignant tumor of meninges Diseases 0.000 claims description 2
- 208000026045 malignant tumor of parathyroid gland Diseases 0.000 claims description 2
- 208000027202 mammary Paget disease Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 206010027191 meningioma Diseases 0.000 claims description 2
- 201000005962 mycosis fungoides Diseases 0.000 claims description 2
- 201000008026 nephroblastoma Diseases 0.000 claims description 2
- 201000008106 ocular cancer Diseases 0.000 claims description 2
- 208000021255 pancreatic insulinoma Diseases 0.000 claims description 2
- 201000001219 parotid gland cancer Diseases 0.000 claims description 2
- 201000002628 peritoneum cancer Diseases 0.000 claims description 2
- 208000028591 pheochromocytoma Diseases 0.000 claims description 2
- 201000002511 pituitary cancer Diseases 0.000 claims description 2
- 201000003437 pleural cancer Diseases 0.000 claims description 2
- 208000030153 prolactin-producing pituitary gland adenoma Diseases 0.000 claims description 2
- 201000000849 skin cancer Diseases 0.000 claims description 2
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 claims description 2
- 229960000553 somatostatin Drugs 0.000 claims description 2
- 206010062261 spinal cord neoplasm Diseases 0.000 claims description 2
- 230000004936 stimulating effect Effects 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 201000003120 testicular cancer Diseases 0.000 claims description 2
- 201000002510 thyroid cancer Diseases 0.000 claims description 2
- 201000006134 tongue cancer Diseases 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 206010046766 uterine cancer Diseases 0.000 claims description 2
- 206010046885 vaginal cancer Diseases 0.000 claims description 2
- 208000013139 vaginal neoplasm Diseases 0.000 claims description 2
- 208000006542 von Hippel-Lindau disease Diseases 0.000 claims description 2
- 201000005102 vulva cancer Diseases 0.000 claims description 2
- 239000013598 vector Substances 0.000 claims 28
- 102000004196 processed proteins & peptides Human genes 0.000 claims 22
- 229920001184 polypeptide Polymers 0.000 claims 20
- 210000000234 capsid Anatomy 0.000 claims 15
- 239000000835 fiber Substances 0.000 claims 10
- 238000000034 method Methods 0.000 claims 9
- 230000003612 virological effect Effects 0.000 claims 4
- 239000013603 viral vector Substances 0.000 claims 3
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 claims 2
- 101150029662 E1 gene Proteins 0.000 claims 2
- 102000043131 MHC class II family Human genes 0.000 claims 2
- 108091054438 MHC class II family Proteins 0.000 claims 2
- 108700019146 Transgenes Proteins 0.000 claims 2
- 238000012217 deletion Methods 0.000 claims 2
- 230000037430 deletion Effects 0.000 claims 2
- 230000001419 dependent effect Effects 0.000 claims 2
- 238000012224 gene deletion Methods 0.000 claims 2
- 230000004048 modification Effects 0.000 claims 2
- 238000012986 modification Methods 0.000 claims 2
- 239000002105 nanoparticle Substances 0.000 claims 2
- 150000007523 nucleic acids Chemical group 0.000 claims 2
- 206010004593 Bile duct cancer Diseases 0.000 claims 1
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 claims 1
- 102000043129 MHC class I family Human genes 0.000 claims 1
- 108091054437 MHC class I family Proteins 0.000 claims 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 claims 1
- 108010039918 Polylysine Proteins 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 230000000840 anti-viral effect Effects 0.000 claims 1
- 208000026900 bile duct neoplasm Diseases 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 239000011248 coating agent Substances 0.000 claims 1
- 238000000576 coating method Methods 0.000 claims 1
- 210000004443 dendritic cell Anatomy 0.000 claims 1
- 238000001361 intraarterial administration Methods 0.000 claims 1
- 239000007928 intraperitoneal injection Substances 0.000 claims 1
- 230000002601 intratumoral effect Effects 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 230000001537 neural effect Effects 0.000 claims 1
- 230000000174 oncolytic effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 229920000656 polylysine Polymers 0.000 claims 1
- 201000009377 thymus cancer Diseases 0.000 claims 1
- 210000002700 urine Anatomy 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 201000010099 disease Diseases 0.000 description 2
- 208000011571 secondary malignant neoplasm Diseases 0.000 description 2
- 208000011581 secondary neoplasm Diseases 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010061523 Lip and/or oral cavity cancer Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 208000004091 Parotid Neoplasms Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 241000315672 SARS coronavirus Species 0.000 description 1
- 208000023915 Ureteral Neoplasms Diseases 0.000 description 1
- 206010046392 Ureteric cancer Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 230000007416 antiviral immune response Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000003254 palate Anatomy 0.000 description 1
- 201000002314 small intestine cancer Diseases 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000029387 trophoblastic neoplasm Diseases 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FI20145449 | 2014-05-19 | ||
| FI20145449 | 2014-05-19 | ||
| PCT/EP2015/060903 WO2015177098A2 (en) | 2014-05-19 | 2015-05-18 | Modified adenoviruses for cancer vaccines development |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020045322A Division JP7030867B2 (ja) | 2014-05-19 | 2020-03-16 | 癌ワクチン開発のための改変アデノウイルス |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017522267A JP2017522267A (ja) | 2017-08-10 |
| JP2017522267A5 true JP2017522267A5 (enExample) | 2019-09-05 |
| JP6705755B2 JP6705755B2 (ja) | 2020-06-03 |
Family
ID=53189815
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016568387A Active JP6705755B2 (ja) | 2014-05-19 | 2015-05-18 | 癌ワクチン開発のための改変アデノウイルス |
| JP2020045322A Active JP7030867B2 (ja) | 2014-05-19 | 2020-03-16 | 癌ワクチン開発のための改変アデノウイルス |
| JP2020089965A Active JP7657028B2 (ja) | 2014-05-19 | 2020-05-22 | 癌ワクチン開発のための改変アデノウイルス |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020045322A Active JP7030867B2 (ja) | 2014-05-19 | 2020-03-16 | 癌ワクチン開発のための改変アデノウイルス |
| JP2020089965A Active JP7657028B2 (ja) | 2014-05-19 | 2020-05-22 | 癌ワクチン開発のための改変アデノウイルス |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US10799568B2 (enExample) |
| EP (1) | EP3145537B1 (enExample) |
| JP (3) | JP6705755B2 (enExample) |
| KR (1) | KR102437072B1 (enExample) |
| CN (2) | CN107073089A (enExample) |
| AU (2) | AU2015263286B2 (enExample) |
| CA (1) | CA2949174A1 (enExample) |
| ES (1) | ES2714921T3 (enExample) |
| NZ (1) | NZ726112A (enExample) |
| RU (1) | RU2695375C2 (enExample) |
| WO (1) | WO2015177098A2 (enExample) |
| ZA (1) | ZA201607715B (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201507393TA (en) | 2013-03-14 | 2015-10-29 | Salk Inst For Biological Studi | Oncolytic adenovirus compositions |
| JP6705755B2 (ja) * | 2014-05-19 | 2020-06-03 | バロ セラピューティクス オイＶａｌｏ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｏｙ | 癌ワクチン開発のための改変アデノウイルス |
| ES2899913T3 (es) | 2014-09-24 | 2022-03-15 | Salk Inst For Biological Studi | Virus tumorales oncolíticos y métodos de uso |
| EP3363447A4 (en) * | 2015-10-12 | 2019-07-03 | Industry - University Cooperation Foundation Hanyang University | ADENOVIRUS COMPLEX FOR TRANSFER AND GENE THERAPY |
| EP3390645B1 (en) | 2016-02-23 | 2022-09-14 | Salk Institute for Biological Studies | Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics |
| WO2017147265A1 (en) | 2016-02-23 | 2017-08-31 | Salk Institute For Biological Studies | High throughput assay for measuring adenovirus replication kinetics |
| GB201616365D0 (en) * | 2016-09-27 | 2016-11-09 | Helsingin Yliopisto | Non-genetic modification of enveloped viruses |
| AU2017375633C1 (en) | 2016-12-12 | 2023-04-27 | Salk Institute For Biological Studies | Tumor-targeting synthetic adenoviruses and uses thereof |
| EP3675902A4 (en) | 2017-08-28 | 2021-06-23 | Board of Trustees of Michigan State University | COMPOSITIONS AND METHODS OF TREATMENT OF CANCER AND INFECTION USING BACTERIOPHAGE AND THEIR MUTANTS |
| US20200397892A1 (en) * | 2018-02-22 | 2020-12-24 | Turnstone Limited Partnership | Oncolytic viruses as adjuvants |
| GB201804468D0 (en) * | 2018-03-21 | 2018-05-02 | Valo Therapeutics Oy | PeptiCRAd Cancer Therapy |
| GB201804473D0 (en) * | 2018-03-21 | 2018-05-02 | Valo Therapeutics Oy | Modified oncolytic adenoviruses |
| BR112020019942A2 (pt) | 2018-04-09 | 2021-01-26 | Salk Institute For Biological Studies | composições de adenovírus oncolítico com propriedades de replicação aprimoradas |
| CN111743923B (zh) * | 2019-03-27 | 2024-11-08 | 北京康万达医药科技有限公司 | 包含分离的重组溶瘤腺病毒和免疫细胞的治疗剂及其应用 |
| GB201907413D0 (en) * | 2019-05-24 | 2019-07-10 | Univ Helsinki | Viral vector |
| US20230144068A1 (en) * | 2020-03-31 | 2023-05-11 | Kaneka Corporation | Method for preparing modified vector and method for modifying vector |
| GB202006760D0 (en) | 2020-05-07 | 2020-06-24 | Univ Helsinki | Bioinformatics |
| GB202013834D0 (en) | 2020-09-03 | 2020-10-21 | Valo Therapeutics Oy | PeptiVAX therapy |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6569426B2 (en) * | 1997-04-03 | 2003-05-27 | Genzyme Corporation | Tresyl-monomethoxypolyethylene glycol-modified viruses having viral infectivity |
| WO1999025379A1 (en) * | 1997-11-14 | 1999-05-27 | Euro-Celtique, S.A. | Modified antibodies with enhanced ability to elicit an anti-idiotype response |
| EP1108047A1 (en) * | 1998-08-27 | 2001-06-20 | Aventis Pharma S.A. | Targeted adenovirus vectors for delivery of heterologous genes |
| KR100773109B1 (ko) * | 1999-05-06 | 2007-11-02 | 웨이크 포리스트 유니버시티 | 면역 반응을 유발하는 항원을 동정하기 위한 조성물과 방법 |
| AU2001234981A1 (en) | 2000-02-09 | 2001-08-20 | Genvec, Inc. | Adenoviral capsid containing chimeric protein ix |
| DE60142840D1 (de) * | 2000-09-08 | 2010-09-30 | Univ Texas | Durch phagendisplay identifizierte zielpeptide des menschen und der maus |
| AU2002308713B2 (en) * | 2001-06-22 | 2008-05-15 | The Trustees Of The University Of Pennsylvania | Methods of inducing a cytotoxic immune response and recombinant simian adenovirus compositions useful therein |
| US20040009939A1 (en) * | 2002-03-05 | 2004-01-15 | Board Of Regent, The University Of Texas System | Methods of enhancing immune induction involving MDA-7 |
| EP1497412A4 (en) * | 2002-04-30 | 2006-11-22 | Avior Therapeutics Inc | ADENOVIRUS VECTORS USED IN IMMUNOTHERAPY |
| US20040102382A1 (en) * | 2002-11-27 | 2004-05-27 | Transgene, S.A. | Targeting peptides |
| US7776322B2 (en) * | 2004-08-16 | 2010-08-17 | Stefan Kochanek | Modified viral vector particles |
| US20060045881A1 (en) * | 2004-08-26 | 2006-03-02 | Board Of Regents, The University Of Texas System | Anti-cancer vaccines |
| EP1985708B1 (en) | 2007-04-27 | 2015-04-15 | Universität Rostock | Selective targeting of viruses to neural precursor cells |
| WO2009117656A2 (en) | 2008-03-21 | 2009-09-24 | Vectorlogics,Inc. | Capsid-incorporated antigen for novel adenovirus vaccine |
| ES2335077B1 (es) | 2008-12-30 | 2011-02-02 | Instituto Aragones De Ciencias De La Salud | Formulaciones para el recubrimiento y transporte de diversos elementos hacia los tumores. |
| WO2011017162A2 (en) * | 2009-08-03 | 2011-02-10 | The Johns Hopkins University | Methods for enhancing antigen-specific immune responses |
| RU2013118723A (ru) * | 2010-09-24 | 2014-10-27 | Онкос Терапьютикс Ой | Онколитические аденовирусные векторы, кодирующие моноклональные антитела против ctla-4 |
| AU2011306846B2 (en) * | 2010-09-24 | 2015-05-14 | Oncos Therapeutics Oy | Oncolytic adenoviral vectors and methods and uses related thereto |
| US20140140962A1 (en) * | 2011-04-29 | 2014-05-22 | The Research Foundation Of State University Of New York | Viruses modified with unnatural moieties and methods of use thereof |
| US20120308660A1 (en) * | 2011-06-02 | 2012-12-06 | Paxvax, Inc. | Nanocoatings for biological materials |
| JP6705755B2 (ja) * | 2014-05-19 | 2020-06-03 | バロ セラピューティクス オイＶａｌｏ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｏｙ | 癌ワクチン開発のための改変アデノウイルス |
-
2015
- 2015-05-18 JP JP2016568387A patent/JP6705755B2/ja active Active
- 2015-05-18 WO PCT/EP2015/060903 patent/WO2015177098A2/en not_active Ceased
- 2015-05-18 US US15/312,388 patent/US10799568B2/en active Active
- 2015-05-18 RU RU2016147003A patent/RU2695375C2/ru active
- 2015-05-18 CN CN201580026994.7A patent/CN107073089A/zh active Pending
- 2015-05-18 ES ES15723503T patent/ES2714921T3/es active Active
- 2015-05-18 NZ NZ726112A patent/NZ726112A/en unknown
- 2015-05-18 AU AU2015263286A patent/AU2015263286B2/en active Active
- 2015-05-18 CA CA2949174A patent/CA2949174A1/en active Pending
- 2015-05-18 KR KR1020167035173A patent/KR102437072B1/ko active Active
- 2015-05-18 CN CN202511457024.4A patent/CN121313807A/zh active Pending
- 2015-05-18 EP EP15723503.7A patent/EP3145537B1/en active Active
-
2016
- 2016-11-09 ZA ZA2016/07715A patent/ZA201607715B/en unknown
-
2020
- 2020-03-16 JP JP2020045322A patent/JP7030867B2/ja active Active
- 2020-05-22 JP JP2020089965A patent/JP7657028B2/ja active Active
- 2020-06-10 AU AU2020203816A patent/AU2020203816B2/en active Active
- 2020-09-02 US US17/009,929 patent/US11730798B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020143128A5 (enExample) | ||
| RU2016147003A (ru) | Покрытые онколитические аденовирусы для пртивораковых вакцин | |
| FI3768830T3 (fi) | Syöpäterapia | |
| JP2012513209A5 (enExample) | ||
| JP2017006120A5 (enExample) | ||
| FI3737403T3 (fi) | Modifioituja adenoviruksia | |
| RU2013118724A (ru) | Онколитические аденовирусные векторы и связанные с ними способы и применения | |
| JP2019531728A5 (enExample) | ||
| RU2017134275A (ru) | Онколитические аденовирусы, кодирующие биспецифические антитела, а также способы и применения, связанные с ними | |
| JP2014207903A5 (enExample) | ||
| JP2017528117A5 (enExample) | ||
| SA518391109B1 (ar) | Kras مستقبلات الخلايا التائية التي تميز hla-cw8 المطفرة المقيدة بـ | |
| JP2012516682A5 (enExample) | ||
| JP2017524380A5 (ja) | 腫瘍血管遮断剤であるポリペプチド、遺伝子、発現ベクター、腫瘍血管遮断剤の組成物、及び腫瘍血管遮断剤であるポリペプチドの調製方法 | |
| CA2593684A1 (en) | Cancer-targeted viral vectors | |
| JP2015520178A5 (enExample) | ||
| Sakkas et al. | Safety and efficacy of suicide gene therapy with adenosine deaminase 5-fluorocytosine silmutaneously in in vitro cultures of melanoma and retinal cell lines | |
| Selmi | The evidence does not support a viral etiology for primary biliary cirrhosis | |
| KR102106619B1 (ko) | 유전자 전달 및 유전자 치료를 위한 아데노바이러스 복합체 | |
| BR112020019322B1 (pt) | Adenovírus modificado, composição farmacêutica compreendendo o mesmo e uso | |
| Xian et al. | Biomarkers and molecular imaging in gastrointestinal cancers | |
| Phua et al. | 477. ANGPTL4 limits the extent of colonic inflammation | |
| WO2020212505A1 (en) | Oncolytic adenoviral vector expressing peptidylarginine deiminase and tissue inhibitor of metalloproteinase | |
| RU2020131337A (ru) | Модифицированные онколитические аденовирусы | |
| Choi et al. | 129. Oncolytic Adenovirus Expressing IL-23 and p35 Elicits IFN-γ-and TNF-a-Co-Producing T Cell-Mediated Antitumor Immunity |